Replies to post #109742 on Biotech Values

[jb_118]

>think this is MNTA's way of getting teva's capabilities in the public domain<

I'm not of that opinion

Whatever it is, I'm not exactly sure how TEVA defends the suit without putting their capabilities in the public domain. MNTA just went all in and they're calling for the cards to be laid on the table.

I like this. It's a great way to force some clarity into the t-enox overhang, rather than just letting the street believe TEVA constantly saying they're about to get approval. I'm not sure it would block TEVA approval or keep TEVA from launching at-risk, but it ups the ante if they do with treble damages on the table, which might be about $150M to MNTA per quarter.

If TEVA does get approval, it may keep SNY from launching an AG while the litigation is still pending.

Wonder if NVS will split litigation costs 55/45

[DewDiligence]

MNTA’s lawsuit has a business rather than a regulatory impetus, IMO. I would be willing to bet MNTA knows that Teva’s Lovenox knockoff is not going to pass muster with the FDA. However, the uncertainty surrounding Teva’s assertions vis-à-vis Lovenox—and the parroting of these assertions by some sell-side analysts—has undermined the conduct of MNTA’s business and, in particular, has made it harder for MNTA to ink partnership deals for FoB’s, M118, and M402.

To get full value for its proprietary technology, MNTA must convince prospective partners that the technology is both valuable and unique, whch is hard to accomplish while Teva is publicly spouting BS about its own Lovenox application.